DMARDSKA - Drug MOA Methotrexate Methotrexate competitively...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
MOA Indications Side Effects Contraindicati ons Dosage Monitoring Other Methotrexate Methotrexate competitively inhibits dihydrofolate reductase, which is the enzyme responsible for converting folic acid to reduced folate cofactors (i.e., tetrahydrofolat e).Some of these reactions influence cell proliferation including the synthesis of thymidylic acid, which results in a greater inhibition of DNA synthesis than RNA synthesis. ALL NH- Lymph oma Head and neck cancer (epider moid) Bladde r cancer Breast cancer Lung cancer Osteo genic sarco ma Crohn diseas e Ulcerat ive colitis Ectopi c pregna ancy Psoriasis Stomat itis Esoph agitis oral ulcers Nause a/Vomi ting hepaot oxicity Alopec ia Ameno rrhea anphyl actoid reactio n anemi a anorex ia aplasti c anemi a AIDS Alcoholism Anemia Breast feeding Liver disease Immunosuppr ession state Pregnancy Neutropenia thrombocytop enia. Dosage are
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 02/18/2012 for the course PAS 600 - 601 taught by Professor Garrubba during the Fall '10 term at Chatham University.

Page1 / 4

DMARDSKA - Drug MOA Methotrexate Methotrexate competitively...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online